Bristol Pulls Serzone; Cites Generic Erosion, Not Safety Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
In a letter to wholesalers, Bristol said the antidepressant will no longer be shipped after June 14. Public Citizen called the withdrawal inadequate since the company is not ordering a recall and nefazodone generics are still available.
You may also be interested in...
Emsam Deal Marks Bristol's Return To The Antidepressant Market
Under an agreement with the Mylan/Watson joint venture Somerset, Bristol will handle all marketing and detailing of the selegiline transdermal patch, which has been "approvable" at FDA since February 2004. Bristol left the antidepressant category in June when it stopped selling Serzone.
Emsam Deal Marks Bristol's Return To The Antidepressant Market
Under an agreement with the Mylan/Watson joint venture Somerset, Bristol will handle all marketing and detailing of the selegiline transdermal patch, which has been "approvable" at FDA since February 2004. Bristol left the antidepressant category in June when it stopped selling Serzone.
Serzone Settlement Pending: Bristol Would Pay “At Least” $70 Mil.
Bristol-Myers Squibb is offering to pay "at least" $70 mil. to resolve product liability claims related to the antidepressant Serzone (nefazodone) under a proposed settlement awaiting approval in West Virginia federal court